Goldman Sachs says this ASX 200 stock is a buy with 25%+ upside

Let's see why the broker is bullish on this name right now.

| More on:
Two brokers analysing stocks.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Challenger Ltd (ASX: CGF) shares have been out of form in recent months.

So much so, the ASX 200 stock has pulled back 20% from its 52-week high.

This has caught the attention of analysts at Goldman Sachs, which believe that it could have created a buying opportunity for investors.

What is Goldman saying about this ASX 200 stock?

According to a note out of the investment bank this morning, its analysts believe that this pullback has unjustified and dragged the annuities company's shares to an attractive level. Particularly given its improving return on equity (ROE).

Commenting on its de-rating, the broker said:

Valuation appeal noting improved earnings / ROE while valuation has derated: CGF's 1-year forward P/E has fallen to ~10x against a backdrop of improving normalised ROE toward target in FY25 and COE margin (without material normalised capital returns) and improved normalised earnings.

Goldman also highlights that the ASX 200 stock's capital position remains strong. It adds:

We expect 1H25 capital position to be strong and broadly stable from 1Q25 perhaps ~1.6x vs. target of 1.3-1.7x: This can help fund earnings growth into 2H25 and FY26 through book growth / asset risk up; offsetting the impact of lower cash rates. On MTMs, we note slightly negative asset experience, NB strain as well as negative illiquidity premium and life risk liability movements (FX). Combined with the dividend payment, we expect this to offset normalised NPAT resulting in a stable capital position.

Big returns

The broker is expecting some big returns from the ASX 200 over the next 12 months.

This morning, Goldman has retained its buy rating with a trimmed price target of $7.60. Based on its current share price of $6.02, this implies potential upside of 26% for investors over the next 12 months.

In addition, the broker is forecasting dividend yields of 4.4% in FY 2025 and then 4.6% in FY 2026. This brings the total potential 12-month return to over 30% for investors.

Commenting on its buy recommendation, the broker said:

We are Buy rated on the stock. We like CGF because: 1) it has exposure to the superannuation market across Life and Funds Management; 2) Yields are supportive of a favorable sales environment for retail annuities; 3) annuity book growth looks well-supported through a diversified distribution strategy / capital position.

Downside risks: 1) Post tax statutory ROE, which has been lagging normalized ROEs, which in turn has been lagging targets (but expected to be met in FY25); 2) weak fund management flows; 3) exposure to property, alternatives and fixed income credit spreads in an uncertain economic environment which can impact capital.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has recommended Challenger. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a group of people stand examining a large glowing cystral ball held in the hands of one of the group members while the others regard it with various expressions of wonder, curiousity and scepticism.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Broker Notes

Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare…

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Broker Notes

Goldman Sachs just downgraded these ASX 200 stocks

Let's see why the broker isn't feeling bullish about these stocks anymore.

Read more »

A happy young woman in a red t-shirt hold up two delicious burritos.
Broker Notes

Guzman Y Gomez shares: Overvalued or still a buy?

Is the GYG valuation too spicy?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Buy this ASX 300 stock after 'milestone' contract win

Goldman Sachs is feeling bullish about this stock. Let's see what the broker is saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

3 of the best ASX 200 shares to buy in January

Bell Potter thinks these could be top picks for investors in 2025.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Consumer Staples & Discretionary Shares

Down 18% in a week: Broker says buy this ASX 200 stock now

Bell Potter thinks investors should be buying the dip.

Read more »